Myeloproliferative Neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—Myelofibrosis, Essential Thrombocythemia (ET), and Polycythemia vera (PV)—affect approximately 13,000, 134,000, and 148,000 patients in the United States, respectively.
To provide clinicians with the most up-to-date and comprehensive treatment recommendations, the National Comprehensive Cancer Network® (NCCN®) today published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MPN to specifically outline diagnosis, treatment, and supportive care strategies for Myelofibrosis. Myelofibrosis is a type of MPN that is the result—in most cases—of one of three genetic mutations within the JAK2 signaling pathway. Comprehensive recommendations for the management of ET and PV will be included in the subsequent versions of the NCCN Guidelines® for MPN.